Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies

August 9, 2016 7:01 AM

27 0

TOKYO Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease.

The investigational oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 was discovered by Eisai and is being jointly developed with Massachusetts-based Biogen Inc, Eisai said in a statement.

Read more

To category page